{
  "id": 20483555,
  "title": "Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue",
  "url": "https://urgent.news/2026/11/17/johnson-johnson-vs-pfizer-consistency-vs-volatility-in-revenue-20483555",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-17T18:50:02.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/johnson-johnson-vs-pfizer-consistency-vs-volatility-revenue"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsJohnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue",
        "url": "https://urgent.news/2026/11/17/johnson-johnson-vs-pfizer-consistency-vs-volatility-in-revenue",
        "published": "2026-11-17T18:30:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}